Douglas S. Chapin - Concepedia

Author

Douglas S. Chapin

Also Known As

D. CHAPIN, D. Chapin, D. S. CHAPIN, D. S. Chapin, D.S. Chapin, David S. Chapin, Douglas C. Chapin, Douglas Chapin, Douglas S. Chapin

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Michigan State University

About

Douglas S. Chapin is an author at Pfizer (United States) specializing in medicine, neuroscience, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	1.7K
2	Natural Sciences	5	5	314
3	Engineering	2	2	82
4	Education	1	1	14
5	Health Sciences	1	1	56

Douglas S. Chapin

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia C J Schmidt, Douglas S. Chapin, J. Cianfrogna, Journal of Pharmacology and Experimental Therapeutics	2008	284
Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis Judith A. Siuciak, Douglas S. Chapin, John F. Harms, Neuropharmacology NeuropsychologyPsychiatryPsychotic DisorderPsychotropic MedicationNovel Approach	2006	274
Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function Judith A. Siuciak, Sheryl A. McCarthy, Douglas S. Chapin, Neuropharmacology Altered Striatal FunctionAlzheimer's DiseaseMolecular NeuroscienceNeurochemical BiomarkersSocial Sciences	2006	230
Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1 <i>H</i> -pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia†Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1). Patrick R. Verhoest, Douglas S. Chapin, Michael L. Corman, Journal of Medicinal Chemistry	2009	201
Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease Dane Liston, Jann A. Nielsen, Anabella Villalobos, European Journal of Pharmacology Alzheimer's DiseaseMedicineDementiaSelective Acetylcholinesterase InhibitorsVascular Dementia	2003	191
Reduction of Brain Kynurenic Acid Improves Cognitive Function Rouba Kozak, Brian Campbell, Christine A. Strick, Journal of Neuroscience Synaptic TransmissionNeurotransmitterClinical NeuroscienceSynaptic SignalingSocial Sciences	2014	172
CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity Judith A. Siuciak, Douglas S. Chapin, Sheryl A. McCarthy, Neuropharmacology NeuropsychologyPsychoactive DrugPsychiatryMedicinePsychopharmacology	2006	131
Novel Benzisoxazole Derivatives as Potent and Selective Inhibitors of Acetylcholinesterase Anabella Villalobos, James F. Blake, Christopher K. Bíggers, Journal of Medicinal Chemistry	1994	109
Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme Judith A. Siuciak, Sheryl A. McCarthy, Douglas S. Chapin, Psychopharmacology Molecular NeuroscienceBiochemistryNeurotransmitterMolecular BiologyMice Deficient	2007	108
Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase John Lowe, Robert Archer, Douglas S. Chapin, Journal of Medicinal Chemistry Medicinal ChemistryCalcium-independent Phosphodiesterase EnzymeBiochemistryMedicineNatural Sciences	1991	89

Page 1